A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Lilly

Status and phase: Completed; Phase 1

Conditions: Non-Small-Cell Lung Carcinoma

Treatments: Drug: Cetuximab + Gefitinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00162318

CA225-064

Details and patient eligibility

About

The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with advanced or metastatic non small cell lung cancer.
• Subjects should have had at least one prior chemotherapy with a platinum based therapy.

Exclusion criteria

• Subjects are excluded from this study if they do not have non small cell lung cancer that is advanced or metastatic or have not had at least one prior platinum based chemotherapy.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Cetuximab + Gefitinib